Мы используем файлы cookie.
Продолжая использовать сайт, вы даете свое согласие на работу с этими файлами.
Girentuximab
Другие языки:

Girentuximab

Подписчиков: 0, рейтинг: 0
Girentuximab
Monoclonal antibody
Type Whole antibody
Source Chimeric
Target CA-IX
Clinical data
Trade names Rencarex
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
Chemical and physical data
Formula C6460H10006N1718O2018S48
Molar mass 145566.00 g·mol−1
 ☒NcheckY (what is this?)  (verify)

Girentuximab (trade name Rencarex) is a chimeric IgG1 monoclonal antibody to carbonic anhydrase IX (CAIX). CAIX is expressed on the surface of most renal cancer cells and is hypothesized to be on the surface of other tumor cells. It is investigational agent in clinical trials for renal cell carcinoma. Its development was suspended as a "naked" or unconjugated antibody during phase III trials due to efficacy.

Girentuximab was originally developed by Wilex AG, Germany. It was granted fast track status and orphan drug designation by the FDA for renal cancer. In January 2017, Telix Pharmaceuticals Limited, an Australian biotechnology company, announced that it had in-licensed Girentuximab for use as a radioimmunoconjugate.

It triggers antibody-dependent cell-mediated cytotoxicity (ADCC). It does this by activating natural killer cells by binding to carbonic anhydrase IX.



Новое сообщение